Previous studies have shown that among DLBCL patients treated with R-CHOP or R-CHOP-like therapy, patients with the GCB phenotype exhibited favorable outcomes [12,26,29], contradicting our findings. Here, DDIT3 is linked to diffuse large B-cell lymphoma.